Company Human Genome Sciences
Equities
US4449031081
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2012 | Actelion Ltd : Exclusive: Human Genome rejected Amgen's $7 billion bid in 2010: sources | RE |
2012 | BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion | RE |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 200,202,597 | 199,790,772 ( 99.79 %) | 0 | 99.79 % |
Sector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- Stock
- Company Human Genome Sciences